A new option for millions looking to try those popular weight loss drugs without having to use a needle. The FDA approving Eli Liy's new GLP1 pill called FO set to hit the market next week. Feoo's selling point takes convenience one step further.Unlike WGOi, you don't have to take FO on an empty stomach and then wait 30 minutes to eat or drink. While not as effective as the injections, both pills help people lose weight. Studies show patients who took the highest dose of Fondo lost 12% of their body weight ...

Another pill to fight obesity won US approval, pitting Lilly’s Foundayo against Novo’s Wegovy pill in the race to dominate a market worth billions. Patients and consumers may also be winners, as prices fall and selection expands. https://t.co/1upjiYnPww ...

Of course, we were expecting approval for Lilly's product. We're proud to have pioneered this category, both with the injectable form being the first to introduce Wegovy injectable back in 2021 and then being the first to introduce an oral pill form version of whole GOBY. So we're excited about, you know, our benefits for consumers that are in search of medicine for weight loss.The Wegovy pill is highly efficacious. It is 17% weight loss observed with the pill, which is injectable type efficacy. Wegovy is t ...

The FDA approved Eli Lilly’s new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market https://t.co/1j0gqhoXlH ...

FDA Approves Eli Lilly’s Weight Loss Pill—Second Weight GLP-1 Drug In Pill Formhttps://t.co/p5uBtpdUYU https://t.co/DyOwW2Tpvb ...

Eli Lilly Chair & CEO Dave Ricks tells CNBC’s Angelica Peebles that with the approval of the company’s GLP-1 pill, orforglipron, they already have the scale necessary to supply the medicine to the globe. Ricks says that while 1 in 10 Americans are currently using a GLP-1, in China only 0.5% of the population has tried one, pointing to a large untapped market opportunity internationally. ...

Eli Lilly & Co.’s weight-loss pill won US approval, ratcheting up pressure on Novo Nordisk A/S, which launched an obesity pill earlier this year. https://t.co/FDknJHod96 ...

All right, let's get to it. A mad dash before we get you to the opening bell a little more than two minutes from now. Talk a little Lily.Of course, they did a deal a couple of days ago as well in the biotech area. >> You know, one of the things that you you kind your eyes glaze over these deals that are under 10 billion. They bought Centessa for 7.8% billion.I just said, "Oh, it's a sleep disorder thing." No, it's a peptide uh that impacts brain for many, many different ways, not just for sleep. And a lot o ...

Eli Lilly’s Zepbound is helping to solve one of the most intractable health challenges of our time: Obesity. Now, the drugmaker hopes to crack another significant public health problem: Sleep disorders. https://t.co/olBNCxJHzK ...

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA Industry: Kahn Swick & Foti, LLC Mar 31, 2026 10:19 PM Eastern Daylight Time Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA Share NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr. ...